Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

A variety of approaches to measure the efficacy of PARP inhibitors

Dr Elisabetta Leo - AstraZeneca, Cambridge, UK

A variety of approaches to measure the efficacy of PARP inhibitors ( Dr Elisabetta Leo - AstraZeneca, Cambridge, UK )

Development and clinical indications of PARP inhibitors

Dr Mark O'Connor - AstraZeneca, Cambridge, UK

Development and clinical indications of PARP inhibitors ( Dr Mark O'Connor - AstraZeneca, Cambridge, UK )

Mechanisms and prospects of a novel CDK9 inhibitor for DLBCL

Dr Susan Galbraith - AstraZeneca, Cambridge, UK

Mechanisms and prospects of a novel CDK9 inhibitor for DLBCL ( Dr Susan Galbraith - AstraZeneca, Cambridge, UK )

Front-line therapy of DIPG using IDO inhibitor with radiation and chemotherapy

Dr Theodore Johnson - Georgia Cancer Center, Augusta, USA

Front-line therapy of DIPG using IDO inhibitor with radiation and chemotherapy ( Dr Theodore Johnson - Georgia Cancer Center, Augusta, USA )

Impact of microbiome on head and neck cancers

Dr Young Jun Kim - Vanderbilt-Ingram Cancer Center, Nashville, USA

Impact of microbiome on head and neck cancers ( Dr Young Jun Kim - Vanderbilt-Ingram Cancer Center, Nashville, USA )

First-in-human trial results of RET targeted BLU-667

Prof Vivek Subbiah - MD Anderson Cancer Center, Houston, USA

First-in-human trial results of RET targeted BLU-667 ( Prof Vivek Subbiah - MD Anderson Cancer Center, Houston, USA )

Treating RET alterations with novel therapy BLU-667

Prof Vivek Subbiah - MD Anderson Cancer Center, Houston, USA

Treating RET alterations with novel therapy BLU-667 ( Prof Vivek Subbiah - MD Anderson Cancer Center, Houston, USA )

AKT inhibitors in research and application

Dr Brian Schwartz - ArQule, Burlington, USA

AKT inhibitors in research and application ( Dr Brian Schwartz - ArQule, Burlington, USA )

Tandem duplications in triple negative breast cancer

Dr Ed Liu - The Jackson Laboratory, Bar Harbor, USA

Tandem duplications in triple negative breast cancer ( Dr Ed Liu - The Jackson Laboratory, Bar Harbor, USA )

Increasing diversity through the NCI SBIR development centre

Dr Christie Canaria - National Cancer Institute, Rockville, USA

Increasing diversity through the NCI SBIR development centre ( Dr Christie Canaria - National Cancer Institute, Rockville, USA )

The importance of online patient groups and 'The ROS1ders'

Janet Freeman-Daily - The ROS1ders

The importance of online patient groups and 'The ROS1ders' ( Janet Freeman-Daily - The ROS1ders )

Effects of dasatinib on xenograft lung tumour models with YES1 overexpression

Dr Irati Garmendia - University of Navarra, Pamplona, Spain

Effects of dasatinib on xenograft lung tumour models with YES1 overexpression ( Dr Irati Garmendia - University of Navarra, Pamplona, Spain )

More from ecancer